Who
Mary Miller
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Acrivon Therapeutics; General Counsel & Corp Sec, Butterfly Network.
In numbers
- Trades disclosed
- 48
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $103K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 12 Feb 2021
- Last trade
- 5 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 7 Oct 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $585294 at $1.99 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $372185 at $2.01 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $372185 at $2.01 | filing |
| 21 Jul 2026filed 23 Jul 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,008573 at $1.76 | filing |
| 21 Jul 2026filed 23 Jul 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,008573 at $1.76 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —49,830 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —49,830 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $353184 at $1.92 | filing |
| 14 May 2026filed 18 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $353184 at $1.92 | filing |
| 17 Apr 2026filed 21 Apr 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $993558 at $1.78 | filing |
| 17 Apr 2026filed 21 Apr 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $993558 at $1.78 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —129,760 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —129,760 at $0.00 | filing |
| 14 Feb 2026filed 18 Feb 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $354217 at $1.63 | filing |
| 14 Feb 2026filed 18 Feb 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $354217 at $1.63 | filing |
| 17 Jan 2026filed 21 Jan 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,305659 at $1.98 | filing |
| 17 Jan 2026filed 21 Jan 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,305659 at $1.98 | filing |
| 14 Nov 2025filed 18 Nov 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $412184 at $2.24 | filing |
| 17 Oct 2025filed 21 Oct 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,010558 at $1.81 | filing |
| 1 Oct 2025filed 3 Oct 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $514284 at $1.81 | filing |
News
Nikki Budzinksi, Mary Miller both face challengers - Illinois Times, the capital city's source of news, politics, arts, entertainment, cultureillinoistimes.com · 22 Oct 2026GOP Rep. Mary Miller Introduces Bill to Protect Parents Who Reject Child Gender Transitionsbreitbart.com · 13 Oct 2026
2 headlines in the last 90 days name Mary Miller; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.